Product Description: Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM. Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood[1]. Remibrutinib has the potential for Chronic urticaria (CU) treatment[2].
Applications: COVID-19-immunoregulation
Formula: C27H27F2N5O3
References: [1]Daniela Angst, et al. Novel amino pyrimidine derivatives. Patent WO2015079417A1./[2]Kolkhir P, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2019 Aug 23.